David J Kwiatkowski Selected Research

MTOR Inhibitors

1/2022	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
1/2021	Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
1/2020	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
1/2019	Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
1/2018	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
10/2017	Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.
9/2017	Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells.
12/2016	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.
1/2016	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
1/2015	mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David J Kwiatkowski Research Topics

Disease

105	Tuberous Sclerosis (Bourneville's Disease) 01/2022 - 03/2002
92	Neoplasms (Cancer) 01/2022 - 03/2002
24	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 01/2022 - 08/2002
20	Epilepsy (Aura) 01/2022 - 12/2002
19	Angiomyolipoma 01/2022 - 10/2002
17	Hamartoma 09/2017 - 03/2002
16	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 11/2010
16	Lung Neoplasms (Lung Cancer) 10/2020 - 12/2012
12	Intellectual Disability (Idiocy) 01/2022 - 07/2005
12	Seizures (Absence Seizure) 01/2022 - 09/2002
11	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 03/2002
11	Carcinogenesis 01/2021 - 07/2009
11	Autistic Disorder (Autism) 01/2020 - 12/2002
9	Urinary Bladder Neoplasms (Bladder Cancer) 11/2021 - 01/2013
7	Carcinoma (Carcinomatosis) 03/2022 - 01/2013
7	Perivascular Epithelioid Cell Neoplasms 11/2021 - 02/2010
7	Adenocarcinoma 03/2018 - 06/2013
6	Angiofibroma 01/2022 - 04/2014
6	Autism Spectrum Disorder 01/2022 - 05/2009
6	Astrocytoma (Pilocytic Astrocytoma) 01/2021 - 12/2004
6	Cystadenoma 03/2015 - 10/2003
6	Asthma (Bronchial Asthma) 09/2004 - 12/2002
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 07/2004
4	Disease Progression 01/2022 - 01/2014
4	Cysts 01/2021 - 01/2014
4	Lung Diseases (Lung Disease) 01/2021 - 04/2007
3	Neurodevelopmental Disorders 10/2021 - 10/2012
3	Respiratory Insufficiency (Respiratory Failure) 11/2020 - 01/2014
3	Adenocarcinoma of Lung 10/2020 - 02/2015
3	Neurologic Manifestations (Neurological Manifestations) 12/2019 - 01/2013
3	Cardiomegaly (Heart Hypertrophy) 03/2015 - 05/2006
3	Infantile Spasms (West Syndrome) 12/2011 - 07/2005
3	Hemangioma (Angioma) 07/2009 - 03/2002
2	Brain Neoplasms (Brain Tumor) 01/2021 - 11/2017
2	Cognitive Dysfunction 10/2020 - 08/2008
2	Neoplasm Metastasis (Metastasis) 01/2020 - 10/2018
2	Hydrocephalus (Hydrocephaly) 12/2019 - 01/2013
2	Hypertension (High Blood Pressure) 12/2016 - 08/2008
2	Leiomyoma (Uterine Fibroids) 10/2015 - 01/2014
2	Brain Diseases (Brain Disorder) 01/2013 - 05/2008
2	Neurocutaneous Syndromes (Phakomatoses) 11/2010 - 03/2010
2	Chronic Obstructive Pulmonary Disease (COPD) 08/2004 - 01/2003
1	Drug Resistant Epilepsy 01/2022

Drug/Important Bio-Agent (IBA)

98	trans-sodium crocetinate (crocetin)IBA 01/2022 - 03/2002
29	Mechanistic Target of Rapamycin Complex 1IBA 01/2022 - 05/2008
29	Sirolimus (Rapamycin)FDA Link 11/2021 - 09/2003
21	TOR Serine-Threonine KinasesIBA 12/2015 - 10/2002
17	lipoarabinomannan (LAM)IBA 01/2022 - 08/2002
17	Proteins (Proteins, Gene)FDA Link 10/2020 - 08/2002
14	MTOR InhibitorsIBA 01/2022 - 05/2008
9	Phosphotransferases (Kinase)IBA 11/2021 - 03/2002
9	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2003
8	Tuberous Sclerosis Complex 2 ProteinIBA 01/2021 - 08/2002
8	Tyrosine Kinase InhibitorsIBA 11/2018 - 06/2013
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2018
6	RNA (Ribonucleic Acid)IBA 01/2021 - 03/2016
6	Pharmaceutical PreparationsIBA 01/2021 - 01/2013
5	Everolimus FDA Link 01/2021 - 05/2008
5	Tuberous Sclerosis Complex 1 ProteinIBA 01/2021 - 10/2002
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2020 - 03/2007
4	Cell-Free Nucleic AcidsIBA 01/2020 - 01/2018
4	NucleotidesIBA 01/2020 - 01/2009
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 09/2003
4	Anaplastic Lymphoma KinaseIBA 02/2015 - 06/2013
4	ErbB Receptors (EGF Receptor)IBA 02/2015 - 06/2013
4	Interferon-gamma (Interferon, gamma)IBA 09/2005 - 10/2002
3	PlatinumIBA 03/2022 - 04/2014
3	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2020
3	ChromatinIBA 01/2021 - 04/2015
3	Vigabatrin FDA Link 01/2021 - 01/2020
3	ParaffinIBA 10/2020 - 01/2012
3	NestinIBA 01/2019 - 11/2011
3	Biological ProductsIBA 05/2012 - 08/2008
2	sapanisertibIBA 01/2022 - 05/2013
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2021 - 01/2018
2	Phenobarbital (Luminal)FDA Link 11/2021 - 10/2015
2	Microphthalmia-Associated Transcription FactorIBA 01/2021 - 01/2017
2	Formaldehyde (Formol)FDA Link 10/2020 - 12/2012
2	Glutathione (Reduced Glutathione)IBA 11/2019 - 01/2018
2	Codon (Codons)IBA 01/2019 - 11/2006
2	VimentinIBA 12/2018 - 07/2014
2	AntigensIBA 01/2018 - 03/2005
2	MicroRNAs (MicroRNA)IBA 01/2018 - 10/2017
2	Messenger RNA (mRNA)IBA 10/2017 - 03/2015
2	Polycomb Repressive Complex 2IBA 01/2017 - 01/2017
2	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 10/2015 - 04/2015
2	Estrogens (Estrogen)FDA Link 01/2014 - 03/2005
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 08/2013 - 08/2007
2	Phosphatidylinositols (Phosphatidylinositol)IBA 03/2013 - 11/2010
2	EndotoxinsIBA 12/2010 - 12/2002
2	Atorvastatin (Lipitor)FDA Link 07/2009 - 10/2007
2	Bronchodilator Agents (Bronchodilators)IBA 08/2004 - 08/2003
2	Epidermal Growth Factor (EGF)IBA 07/2004 - 10/2003
1	enfortumab vedotinIBA 03/2022
1	Cell Adhesion MoleculesIBA 01/2022
1	GenieIBA 01/2022

Therapy/Procedure

34	Therapeutics 03/2022 - 05/2004
2	Immunotherapy 01/2021 - 12/2018
2	Drug Therapy (Chemotherapy) 01/2015 - 04/2014
2	Ligation 01/2013 - 01/2009